{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:34:49Z","timestamp":1792625689088,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients with HF and\/or CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study utilized data from hospital records, claims, and health registers from the US (Optum\u2019s de-identified Market Clarity Data) and Japan (Medical Data Vision). Included patients had an index episode of HK between July 2019 and September 2021 (US), or May 2020 and September 2021 (Japan), with prior diagnosis of HF or CKD (stage 3 or 4), and RAASi use. Risk of a cardiorenal composite outcome (HF emergency visit, HF hospitalization, or progression to end-stage kidney disease) was determined in patients who discontinued RAASi, down-titrated their dose by &gt;\u200925%, or maintained or up-titrated their dose following the HK episode.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 15,488 and 6020 patients were included from the US and Japan, respectively. Prior to the episode of HK, 59% (US) and 27% (Japan) of patients had achieved &gt;\u200950% target RAASi dose. Following the episode of HK, 33% (US) and 32% (Japan) of patients did not fill a new RAASi prescription. Risk of the cardiorenal outcome at 6\u2009months was higher in patients who discontinued or down-titrated versus maintained or up-titrated RAASi treatment both in the US (17.5, 18.3, and 10.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) and in Japan (19.7, 20.0, and 15.1%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HK-related RAASi discontinuation or down-titration was associated with higher risk of cardiorenal events versus maintained or up-titrated RAASi.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-022-03054-5","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T09:04:07Z","timestamp":1674119047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Eiichiro","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Les\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiy","family":"Agiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"J\u00e4rbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles V.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"2","key":"3054_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73\u201387.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3054_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"3054_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00392-008-0668-3","volume":"97","author":"C Werner","year":"2008","unstructured":"Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7):418\u201331.","journal-title":"Clin Res Cardiol"},{"issue":"4S","key":"3054_CR4","first-page":"S1","volume":"98","author":"K Disease","year":"2020","unstructured":"Disease K. Improving global outcomes (KDIGO) diabetes work group: KDIGO 2020 clinical practice guideline for diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1\u2013S115.","journal-title":"Kidney Int"},{"issue":"3S","key":"3054_CR5","first-page":"S1","volume":"99","author":"K Disease","year":"2021","unstructured":"Disease K. Improving global outcomes blood pressure work group: KDIGO 2021 clinical practice guideline for the Management of Blood Pressure in chronic kidney Disease. Kidney Int. 2021;99(3S):S1\u2013S87.","journal-title":"Kidney Int"},{"issue":"36","key":"3054_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"17","key":"3054_CR7","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263\u2013421.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3054_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-018-1648-1","volume":"23","author":"Japanese Society of Nephrology","year":"2019","unstructured":"Japanese Society of Nephrology. Essential points from evidence-based clinical practice guidelines for chronic kidney Disease 2018. Clin Exp Nephrol. 2019;23(1):1\u201315.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"3054_CR9","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","volume":"85","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. Circ J. 2021;85(12):2252\u201391.","journal-title":"Circ J"},{"issue":"6","key":"3054_CR10","first-page":"487","volume":"92","author":"AJ Viera","year":"2015","unstructured":"Viera AJ, Wouk N. Potassium Disorders: Hypokalemia and Hyperkalemia. Am Fam Physician. 2015;92(6):487\u201395.","journal-title":"Am Fam Physician"},{"issue":"3","key":"3054_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol. 2017;46(3):213\u201321.","journal-title":"Am J Nephrol"},{"issue":"6","key":"3054_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000437151","volume":"41","author":"GN Nakhoul","year":"2015","unstructured":"Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, et al. Serum potassium, end-stage renal Disease and mortality in chronic kidney Disease. Am J Nephrol. 2015;41(6):456\u201363.","journal-title":"Am J Nephrol"},{"issue":"6","key":"3054_CR13","doi-asserted-by":"publisher","first-page":"e0218739","DOI":"10.1371\/journal.pone.0218739","volume":"14","author":"K Adelborg","year":"2019","unstructured":"Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients \u2014 a population-based cohort study. PLoS One. 2019;14(6):e0218739.","journal-title":"PLoS One"},{"key":"3054_CR14","doi-asserted-by":"publisher","first-page":"n189","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021;372:n189.","journal-title":"BMJ"},{"issue":"24","key":"3054_CR15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38(24):1883\u201390.","journal-title":"Eur Heart J"},{"issue":"11 Suppl","key":"3054_CR16","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.","journal-title":"Am J Manag Care"},{"issue":"11","key":"3054_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/ejhf.887","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Qualify investigators: Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414\u201323.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"3054_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep. 2019;4(9):1248\u201360.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"3054_CR19","doi-asserted-by":"publisher","first-page":"e005181","DOI":"10.1136\/bmjopen-2014-005181","volume":"4","author":"CA Jackevicius","year":"2014","unstructured":"Jackevicius CA, Wong J, Aroustamian I, Gee M, Mody FV. Rates and predictors of ACE inhibitor discontinuation subsequent to elevated serum creatinine: a retrospective cohort study. BMJ Open. 2014;4(8):e005181.","journal-title":"BMJ Open"},{"issue":"7","key":"3054_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jch.13563","volume":"21","author":"R Pecoits-Filho","year":"2019","unstructured":"Pecoits-Filho R, Fliser D, Tu C, Zee J, Bieber B, Wong MMY, et al. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J Clin Hypertens (Greenwich). 2019;21(7):991\u20131001.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10","key":"3054_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry. Eur J Heart Fail. 2013;15(10):1173\u201384.","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"3054_CR22","doi-asserted-by":"publisher","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8(22):e012655.","journal-title":"J Am Heart Assoc"},{"issue":"4-a Suppl","key":"3054_CR23","first-page":"S2","volume":"23","author":"M Polson","year":"2017","unstructured":"Polson M, Lord TC, Kangethe A, Speicher L, Farnum C, Brenner M, et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney Disease and heart failure. J Manag Care Spec Pharm. 2017;23(4-a Suppl):S2\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"3054_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326.","journal-title":"Eur J Heart Fail"},{"key":"3054_CR25","unstructured":"Sodium zirconium cyclosilicate for treating hyperkalaemia. Technology appraisal guidance [http:\/\/www.nice.org.uk\/guidance\/ta599]. Accessed 21 December 2022."},{"key":"3054_CR26","unstructured":"Patiromer for treating hyperkalaemia. Technology appraisal guidance [http:\/\/www.nice.org.uk\/guidance\/ta623]. Accessed 21 December 2022."},{"key":"3054_CR27","unstructured":"Chronic kidney disease: assessment and management (NICE Guideline 203) [https:\/\/www.nice.org.uk\/guidance\/ng203]. Accessed 21 December 2022."},{"issue":"3","key":"3054_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.12990820","volume":"16","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Talarico R, Tangri N, Leon SJ, Bota SE, Rhodes E, et al. Ambulatory treatments for RAAS inhibitor-related hyperkalemia and the 1-year risk of recurrence. Clin J Am Soc Nephrol. 2021;16(3):365\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3054_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2215\/CJN.06280616","volume":"12","author":"PE Ronksley","year":"2017","unstructured":"Ronksley PE, Tonelli M, Manns BJ, Weaver RG, Thomas CM, MacRae JM, et al. Emergency department use among patients with CKD: a population-based analysis. Clin J Am Soc Nephrol. 2017;12(2):304\u201314.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3054_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022;80(2):164\u2013173.e161.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3054_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ehf2.12244","volume":"5","author":"N Bruno","year":"2018","unstructured":"Bruno N, Sinagra G, Paolillo S, Bonomi A, Corra U, Piepoli M, et al. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ESC Heart Fail. 2018;5(3):267\u201374.","journal-title":"ESC Heart Fail"},{"key":"3054_CR32","unstructured":"FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes [https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease]. Accessed 21 December 2022."},{"key":"3054_CR33","unstructured":"Bayer receives approval in Japan for Kerendia\u2122 (finerenone), a new treatment for adults with chronic kidney disease and type 2 diabetes [https:\/\/media.bayer.com\/baynews\/baynews.nsf\/id\/D9C938D1CCF107DDC125880E002A3958?open&ref=irrefndcd]. Accessed 21 December 2022."},{"issue":"1","key":"3054_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia risk with Finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33(1):225\u201337.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03054-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-03054-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03054-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T09:04:20Z","timestamp":1674119060000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-03054-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3054"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-03054-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Confederation on Harmonization Good Clinical Practice Guidelines, and Good Publication Practice recommendations, and applicable legislation on Non-Interventional Studies and\/or Observational Studies. As this study solely involved secondary analysis of de-identified data, Institutional Review Board approvals or individual patient consent were not needed. According to the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, ethical approval and informed consent do not apply to the use of de-identified secondary data. In the United States, local data source requirements were followed; access to the de-identified data was approved via Optum\u2019s internal HIPAA Disclosure Analysis review process prior to data delivery, and Institutional Review Board approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.K. declares no competing interests.A.R. has received institutional support relating to research grants from Alnylam Pharmaceuticals, AstraZeneca, Bayer, Gilead, GSK, Idorsia Pharmaceuticals Ltd., the National Institutes of Health, Novo Nordisk, Kadmon Corporation (LLC), Omeros Inc., Otsuka Pharmaceuticals, Palladio Biosciences, Pfizer, Protalix Biotherapeutics Ltd., Reata Pharmaceuticals, Regulus Therapeutics, Summit Therapeutics, and Sanofi; consulting fees or support for participation in advisory boards from Akebia, Amgen, Ardelyx, AstraZeneca, Aurinia, Baxter, Chiesi Global Inc., Chinook Therapeutics, Fresenius Medical Care, GSK, Otsuka, Relypsa, Sanofi, Tricida, and Vifor Pharma Inc.; speaker fees from Amgen, AstraZeneca, Aurinia, Bayer, Baxter, Fresenius Medical Care, Genzyme\/Sanofi, Janssen, National Kidney Foundation, Vifor Pharma Inc., and Natera; provision of expert testimony from Quinn Emanuel Urquhart & Sullivan (LLP), and Bowman and Brooke Attorneys at Law; and, for attending meetings and\/or travel from all of the above.T.M. has received honoraria for educational materials from AstraZeneca, Lilly, and Boehringer Ingelheim Japan.M.A. is an employee of AstraZeneca. E.L., A.A., G.C., T.Y., and K.J. are employees of, and hold stock\/stock options in, AstraZeneca.C.V.P. has received consultancy fees from AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}